Robert Bazemore makes Hutchmed deal his grand finale as Epizyme CEO; Black Diamond reshuffles the deck with departures of CMO, CSO
→ One minute, Epizyme CEO Robert Bazemore helped engineer a partnership with Hutchmed on developing Tazverik in China. The next minute, he gave his job to someone else.
Bazemore stepped aside as Epizyme’s chief executive the same day the biotech announced the deal, ceding the throne to Grant Bogle, the chief commercial officer at Tesaro from 2015 until 2019 — the year GlaxoSmithKline’s takeover of the oncology-focused company was completed. Since 2019, Bogle has kept a seat on Epizyme’s board of directors.